Fate Therapeutics Inc (FATE) — Cash Flow-to-Debt Ratio
Fate Therapeutics Inc (FATE) has a Cash Flow-to-Debt Ratio of -0.22x as of September 2025, meaning its operating cash flow of $-24.37 Million could theoretically repay 0% of its total liabilities ($109.61 Million) in one year. Explore Fate Therapeutics Inc (FATE) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Fate Therapeutics Inc Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Fate Therapeutics Inc across 14 annual periods. Also explore FATE total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Fate Therapeutics Inc (2011–2024)
Year-by-year debt coverage analysis for Fate Therapeutics Inc. For market capitalisation and broader financial context, see FATE market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.01x | $-122.87 Million | $121.97 Million | ▼ -5.0% |
| 2023 | -0.96x | $-132.26 Million | $137.80 Million | ▲ +14.3% |
| 2022 | -1.12x | $-248.21 Million | $221.62 Million | ▼ -66.8% |
| 2021 | -0.67x | $-162.87 Million | $242.62 Million | ▼ -307.3% |
| 2020 | -0.16x | $-39.23 Million | $238.01 Million | ▲ +88.6% |
| 2019 | -1.45x | $-83.17 Million | $57.52 Million | ▼ -96.7% |
| 2018 | -0.74x | $-38.65 Million | $52.56 Million | ▲ +44.0% |
| 2017 | -1.31x | $-36.91 Million | $28.10 Million | ▲ +3.6% |
| 2016 | -1.36x | $-29.82 Million | $21.89 Million | ▼ -121.5% |
| 2015 | -0.61x | $-18.40 Million | $29.92 Million | ▲ +37.3% |
| 2014 | -0.98x | $-22.42 Million | $22.86 Million | ▲ +69.8% |
| 2013 | -3.25x | $-15.37 Million | $4.74 Million | ▼ -1462.9% |
| 2012 | -0.21x | $-13.27 Million | $63.90 Million | ▼ -0.1% |
| 2011 | -0.21x | $-12.14 Million | $58.53 Million | — |